——————————————————————————–
Tresiba (insulin degludec) is Novo Nordisk’s long-acting basal insulin, and its retail price has pushed many people with diabetes toward the Tresiba patient assistance program. The Tresiba patient assistance program is part of the broader Novo Nordisk Patient Assistance Program (NPAP), which provides insulin at no cost to qualifying uninsured and underinsured patients whose income falls at or below a set threshold (historically around 400% of the federal poverty level). Combined with the insulin affordability laws and cost caps that have taken effect in recent years, most Americans now have at least one realistic path to more affordable Tresiba. This guide walks through the options. It is prescriber-directed and this site is not affiliated with Novo Nordisk, so confirm current eligibility and prices directly. Our healthcare costs guide covers broader insulin savings strategies.
What the Tresiba Patient Assistance Program Provides
NPAP (the parent program that includes Tresiba) ships insulin at no cost to qualifying patients or their prescribers. Approved patients generally receive a multi-month supply of Tresiba at a time, either in vials or FlexTouch pens depending on the prescription, with no charge for the medication. The program operates under Novo Nordisk’s patient-access infrastructure rather than through a third-party foundation. Exact supply amounts and terms can change, so verify current details when you apply.
Besides Tresiba, the same application generally covers Novo Nordisk’s other insulins, such as Levemir, NovoLog, Fiasp, and the Novolin family. If your doctor prescribes any combination of these, you may be able to apply for them on a single NPAP form. Because Novo Nordisk periodically updates and, in some cases, discontinues specific products, confirm that your prescribed insulin is currently included.
Who Qualifies for the Tresiba Patient Assistance Program
NPAP eligibility generally rests on a few core criteria, and the specifics are updated over time – treat the following as a starting point to verify, not a guarantee. First, you typically must be a U.S. citizen or legal resident. Second, your total household income usually must fall at or below a set percentage of the federal poverty level (commonly cited around 400%). The exact dollar cutoffs are tied to the current-year federal poverty guidelines and to your household size, so check the figure that applies to you at application time (verify current).
Third, insurance status matters: NPAP is generally aimed at people who are uninsured or, for some Medicare Part D enrollees, those who meet specific out-of-pocket and eligibility conditions. Patients with commercial insurance are typically directed to the Novo Nordisk savings card instead, and Medicaid enrollees are usually excluded because Medicaid already covers Tresiba at reduced cost. Because these rules change, confirm the current criteria with Novo Nordisk before assuming you do or do not qualify.
How to Apply for the Tresiba Patient Assistance Program
Processing typically takes a few weeks from submission to first shipment. Begin at NovoCare.com (or call the NovoCare number listed on the site) to find the Patient Assistance Program section and the current application form. Complete the patient section with your personal information, household size, income, and insurance status, and sign any required authorization for income verification.
Your prescribing physician completes the prescriber section with your diagnosis, the specific insulin prescribed, dosing, and quantity. Both sections usually must be submitted together. You will generally need to include proof of income – for example, a copy of your most recent federal tax return, recent pay stubs, or (for patients with no documentable income) a signed attestation explaining your financial situation. Submit the completed application through the channel the current form specifies (secure upload, fax, or mail). Novo Nordisk reviews it and notifies you and your prescriber of the decision.
Alternative Insulin Savings for Tresiba
Several alternatives exist if you do not qualify for NPAP or prefer a faster path. For commercially insured patients, the Novo Nordisk savings card can lower Tresiba copays for eligible users – the advertised copay has commonly been as low as $35 per 30-day supply, subject to eligibility rules and caps (verify current). Enroll through NovoCare; the card applies at participating pharmacies when your prescription is processed through commercial insurance first, and it cannot be used with government insurance such as Medicare or Medicaid.
Medicare Part D enrollees benefit from a $35-per-month cost cap on covered insulin, including Tresiba, under the Inflation Reduction Act. This cap applies regardless of which Part D plan you have, and insulin spending counts toward the redesigned Part D annual out-of-pocket cap (reported at roughly $2,100 for 2026 per CMS – verify current). Medicaid covers Tresiba with minimal or no copay in most states.
State Insulin Affordability Laws
Many states have passed insulin copay caps that limit what commercially insured patients pay for insulin, including Tresiba. The exact cap varies by state – figures such as $25, $30, $35, or $100 per month have been enacted in different states – and these caps generally apply only to state-regulated commercial plans, not to self-funded ERISA employer plans. Because states continue to add and revise these laws, check your own state’s current rule rather than relying on a fixed list.
Contact your state insurance department, or Novo Nordisk’s customer service line listed on NovoCare.com, to confirm whether your state’s cap applies to your specific plan. These laws generally do not help uninsured patients, so NPAP and cash options remain the primary routes for those without coverage.
Cash-Pay and Coupon Options for Tresiba
If NPAP and insurance both fall through, prescription discount coupons (for example, GoodRx or similar cards) can reduce the cash price of Tresiba somewhat, though discounts on branded insulin are typically modest because Tresiba has no generic equivalent. Compare a few cards, since prices vary by pharmacy and change over time.
Novo Nordisk has also offered reduced cash-price programs for its insulins to any U.S. patient with a valid prescription, regardless of insurance status. The specific per-vial and per-pen cash prices under these programs have changed over time, so check the current amount on NovoCare.com rather than relying on an older figure (verify current). For many uninsured patients, a manufacturer cash-price program can beat a discount coupon. See our NovoCare PAP guide and Victoza PAP guide for parallel Novo Nordisk programs.
Frequently Asked Questions
Is the Tresiba patient assistance program really free?
For patients who qualify, NPAP provides Tresiba at no cost, and there is no application fee. The program is funded by Novo Nordisk as part of its patient-assistance commitments. Eligibility rules apply and can change, so confirm current terms.
How long does it take to get approved for the Tresiba PAP?
Most complete applications are processed within a few weeks. Incomplete applications, missing income documentation, or a missing prescriber signature can extend the timeline. Contact NovoCare using the number on their site if you have not heard back within about 30 days.
Can Medicare patients get free Tresiba?
Some Medicare Part D patients may qualify for NPAP if they meet the current criteria, but most Medicare patients are better served by the $35-per-month insulin cap, which applies to Tresiba on all Part D plans. Check your plan’s specifics.
Does the Tresiba PAP cover FlexTouch pens?
Novo Nordisk’s assistance programs have covered both Tresiba vials and FlexTouch pens, with your physician specifying the form on the prescription. Confirm current coverage of your specific formulation when you apply.
What if I don’t qualify for the Tresiba patient assistance program?
If you have commercial insurance, look at the Novo Nordisk savings card. If you have Medicare, use the $35-per-month insulin cap. If you are uninsured and over the income limit, a Novo Nordisk cash-price program or a discount coupon may be your best backup. Compare options for your situation.
The Bottom Line
The Tresiba patient assistance program, part of the Novo Nordisk Patient Assistance Program, provides insulin at no cost to qualifying uninsured and underinsured patients whose income falls under the program’s threshold. Apply through NovoCare.com, coordinate with your prescribing physician, and submit proof of income. Commercially insured patients should look at the Novo Nordisk savings card, Medicare patients can rely on the $35-per-month insulin cap, and anyone outside those programs can consider a Novo Nordisk cash-price program or discount coupon as a backup. Because eligibility, caps, and prices change, verify the current details directly before applying, and let your prescriber guide your insulin decisions.
TL;DR & disclaimer: The Tresiba patient assistance program (part of Novo Nordisk’s NPAP) provides insulin at no cost to qualifying uninsured and underinsured patients – it is not insurance. Eligibility depends on income (commonly around 400% of the federal poverty level), residency, and insurance status, and the exact thresholds change yearly, so verify current terms. A $35-per-month insulin cap applies to Medicare Part D and, through many state laws and manufacturer programs, to many others. Commercially insured patients may use the Novo Nordisk savings card; uninsured patients may use a manufacturer cash-price program. This article is general information, not medical or financial advice; insulin decisions are prescriber-directed, and this site is not affiliated with Novo Nordisk – confirm current eligibility, prices, and details directly.
Sources
- NovoCare / Novo Nordisk – Tresiba savings and assistance (novocare.com)
- Novo Nordisk Patient Assistance Program (NPAP) (novonordisk-us.com)
- CMS – “Inflation Reduction Act and Medicare” / insulin cost cap (cms.gov)
- Medicare.gov – insulin costs (medicare.gov)
- DailyMed / FDA label – insulin degludec (Tresiba) (dailymed.nlm.nih.gov)